Amgen, Inc.

Former Green Beret Mike Berke, an Amgen director, discusses how his military experience influences his work in developing lab automation to support drug discovery. He highlights the similarities between the military and Amgen's mission to serve, emphasizing teamwork, problem-solving, and innovation. Berke's team creates custom solutions for scientists, exemplified by automating a tedious lab task, and he personally connects to Amgen's mission through his family's health challenges.

TEZSPIRE showed significant reduction in nasal polyp size and nasal congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), compared to placebo.

Skyrizi surpasses Humira in sales, causing concerns for adalimumab biosimilar market growth. Despite biosimilars capturing 22% market share by Oct 2024, Skyrizi's rise and product hopping complicate biosimilar sustainability. Clinical trials show Skyrizi's superior efficacy in psoriasis treatment, and policy reforms are advocated to enhance biosimilar access and competition.

Experts discuss tirzepatide's safety and benefits after a UK death linked to the drug, highlighting the need for high-quality trials and the importance of the 'yellow card scheme' for reporting side effects.

Positive Phase 3 WAYPOINT trial results show TEZSPIRE® (tezepelumab-ekko) significantly reduces nasal polyp size and nasal congestion in chronic rhinosinusitis with nasal polyps (CRSwNP) patients, compared to placebo, with a consistent safety profile.

AstraZeneca's Phase III WAYPOINT study of Tezspire in chronic rhinosinusitis with nasal polyps met co-primary endpoints, showing significant reduction in nasal polyps and congestion, with consistent safety profile.

Positive top-line results from the Phase 3 WAYPOINT trial show TEZSPIRE® (tezepelumab-ekko) significantly reduces nasal polyp size and nasal congestion in chronic rhinosinusitis with nasal polyps (CRSwNP) patients compared to placebo, with a consistent safety profile.

Tezspire (tezepelumab) showed significant reduction in nasal polyps and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering a potential new treatment option.

AstraZeneca and Amgen's Tezspire (tezepelumab) met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyp size and congestion. The therapy, a TSLP inhibiting monoclonal antibody, previously received FDA approval for severe asthma and a breakthrough therapy designation for COPD. Tezspire's main competitor is Sanofi and Regeneron's Dupixent, which also treats CRSwCP and other immune-mediated disorders.